araag2/NLI4PR huggingface dataset:
Clinical trial: Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) (NCT01609309)

Eligibility criteria:
Inclusion Criteria:

          -  Age from over 18 to under 75 years

          -  Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or
             poorly differentiated) confirmed pathologically by endoscopic biopsy

          -  cT2-4a, N0-3, M0 at preoperative evaluation according to the AJCC Cancer Staging
             Manual Seventh Edition

          -  Expected curative resection through distal subtotal gastrectomy with D2
             lymphadenectomy

          -  Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale

          -  ASA (American Society of Anesthesiology) score class I, II, or III

          -  Written informed consent

        Exclusion Criteria:

          -  Women during pregnancy or breast-feeding

          -  Severe mental disorder

          -  History of previous upper abdominal surgery (except laparoscopic cholecystectomy)

          -  History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal
             dissection

          -  Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging

          -  History of other malignant disease within past five years

          -  History of previous neoadjuvant chemotherapy or radiotherapy

          -  History of unstable angina or myocardial infarction within past six months

          -  History of cerebrovascular accident within past six months

          -  History of continuous systematic administration of corticosteroids within one month

          -  Requirement of simultaneous surgery for other disease

          -  Emergency surgery due to complication (bleeding, obstruction or perforation) caused by
             gastric cancer

          -  FEV1<50% of predicted values
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 19 Years old.
Subject must be at most 74 Years

Patient description (medical language): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient description (patient's own words): I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Does the patient match the trial criteria? 1
Clinical trial: Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders (NCT04537078)

Eligibility criteria:
Inclusion Criteria:

          -  1. Indicated infertile women for ICSI of poor responders defined by Bologna criteria
             either two or more of the following:(15) (i) advanced maternal age or any other risk
             factor for POR. (ii) a previous POR ; less than 3-5 oocytes retrieved per cycle. (iii)
             an abnormal ovarian reserve test (ORT): AFC less than 5-7 or AMH is less than 1.1
             ng/ml.

        Or two episodes of POR after maximal stimulation are sufficient to define a patient as poor
        responder in the absence of advanced maternal age or abnormal ORT.

        Exclusion Criteria:

        1. Male factor infertility due to azoospermia. 2. Patients with uncorrected uterine
        pathology. 3. Patients with the diagnosis of severe endometriosis. 4. Patients with BMI
        over 35.

        -
Female
Accepts Healthy Volunteers
Subject must be at least 20 Years old.
Subject must be at most 45 Years

Patient description (medical language): A 32-year-old woman comes to the hospital with vaginal spotting.  Her last menstrual period was 10 weeks ago. She has regular menses lasting for 6 days and repeating every 29 days. Medical history is significant for appendectomy and several complicated UTIs. She has multiple male partners, and she is inconsistent with using barrier contraceptives. Vital signs are normal.  Serum β-hCG level is 1800 mIU/mL, and a repeat level after 2 days shows an abnormal rise to 2100 mIU/mL.  Pelvic ultrasound reveals a thin endometrium with no gestational sac in the uterus.

Patient description (patient's own words): I just turned 32 and last morning I woke up with strange blood stains on my underwear. My last periods were more than 2 months ago, which is unusual for me because I used to have regular periods lasting for 6 days every 29 days, more or less. I had several UTIs in the past. I also had appendicitis. I'm currently seeing several men and, to be honest, some of them do struggle to wear a condom. I went to the hospital to check myself up and they told me that my vitals were normal. I also had a blood test on Monday, and my β-hCG level was 1800 mIU/mL, and then on Wednesday, it went up to 2100 mIU/mL. The gynecologist also did an ultrasound and she told me that, hopefully, there was no ovule.

Does the patient match the trial criteria? 1
Clinical trial: Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome (NCT00190658)

Eligibility criteria:
Inclusion Criteria:

          -  Turner Syndrome or SHOX disorder

          -  SHOX: bone age greater than 10 years for boys, greater than 8 years for girls, Turner:
             bone age greater than 9 years

          -  Height below 3rd percentile or height below 10th percentile and growth velocity below
             25th percentile

          -  Prepubertal: For girls, Tanner stage 1, for boys Tanner stage 1 and testicular volume
             no more than 2 mL

        Exclusion Criteria:

          -  GH deficiency or known insensitivity

          -  Evidence of tumor activity

          -  Diabetes mellitus or history of impaired glucose tolerance

          -  Any severe illness known to interfere growth
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 3 Years old.


Patient description (medical language): A 9-year-old girl is brought to the office for evaluation of short stature and overweight body habitus. The patient's mother and father are 170 cm and 181 cm tall, respectively.  On physical examination, the patient's height is in the 5th percentile of her age.  Other findings include low-set ears, a high arched palate, a webbed neck, and cubitus valgus.  Chromosomal analysis reveals a 45, XO karyotype.

Patient description (patient's own words): I took my 9-year-old daughter to the doctor because my mother-in-law kept saying she seemed small and overweight. My husband and I are 170 cm and 181 cm tall, respectively. The physical health highlighted that she is in the 5th percentile of her age. The doctor said that she has low-set ears, a high-arched palate, a webbed neck, and cubitus valgus. She also did a chromosomal analysis, which revealed a 45, XO karyotype.

Does the patient match the trial criteria? 1
Clinical trial: Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid (NCT03812367)

Eligibility criteria:
Inclusion Criteria:

          1. Women at least 50 years of age who are postmenopausal. Postmenopausal is defined as
             being amenorrheic for at a period of at least 12 months.

          2. Diagnosis of osteoporosis by T score of < -2.5 at either lumbar spine or the
             hip/femoral neck, or osteopenia that qualifies for treatment by FRAX calculation
             (10-year risk of hip fracture > 3% and/or major osteoporotic fracture of > 20%).

        3a. Subjects who have had chronic treatment of denosumab (as defined as > 1 year [at least
        3 6-monthly injections]) or zoledronic acid (defined as ≥ 2 years [at least 2 annual
        injections]) . Note: At the time of treatment initiation, subjects must have met criteria
        for on-label use (e.g. criterion 2 above).

        OR 3b. Subjects who are naïve to treatment with denosumab and/or zoledronic acid.

        Exclusion Criteria:

          1. Renal insufficiency, with glomerular filtration rate (GFR) < 35 ml/min.

          2. Hypocalcemia within 6 months of study initiation.

          3. Known hypersensitivity to denosumab or zoledronic acid.

          4. Medications that could alter bone turnover including prednisone, anti-rheumatic
             medications, anti-metabolites (Cytoxan). Subjects who have been on stable doses of
             thyroid replacement or diabetes medications for more than 3 months are eligible.

          5. Evidence of untreated oral cavities or oral infections. Preventative dental exams
             should be performed before starting denosumab or zoledronic acid. Subjects must avoid
             invasive dental procedures during treatment with denosumab or zoledronic acid.
Female
No healthy subjects accepted to join the trial.
Subject must be at least 50 Years old.


Patient description (medical language): A 55-year-old white woman comes for a routine checkup.  She has no significant medical history and does not use tobacco, alcohol, or illicit drugs.  The patient's only medication is an over-the-counter multivitamin.  Family history is notable for a hip fracture in her mother.  Blood pressure is 130/80 mm Hg and pulse is 112/min. She has occasional back pain and lives a sedentary lifestyle with the BMI of 24 Kg/m2. Plain X-ray of the spine shows mild compression fracture at the level of T10. X-ray absorptiometry studies demonstrate abnormally low bone density in the lumbar vertebrae and T-score values below -2.5, which confirms the diagnosis of osteoporosis.

Patient description (patient's own words): I'm a 55-year-old white woman

Does the patient match the trial criteria? 1
Clinical trial: Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography (NCT01561924)

Eligibility criteria:
Inclusion Criteria:

          -  Confirmed diagnosis of congenital haemophilia A or B with a FVIII:C clot activity or
             FIX:C clot activity, respectively, less than 5%

          -  Presently use of activated recombinant human factor VII (NovoSeven®) as haemostatic
             agent for preventive treatment or treatment of bleeding episodes

          -  A documented historical or present record for the presence of inhibitors to factor
             VIII or IX, respectively

          -  A documented history of 2 or more joint bleeding episodes during the preceding 12
             months

          -  Subjects must be in a non-bleeding state (i.e. no clinical manifestations of active
             bleeds)

        Exclusion Criteria:

          -  Subjects who have received any haemostatic treatment for a bleeding episode within the
             last 7 days prior to this trial

          -  Immune tolerance therapy within the last 30 days prior to this trial

          -  Clinically relevant coagulation disorders other than congenital haemophilia A or B

          -  Thrombocytopenia (platelet count below 60,000 platelets/mcl)

          -  Prophylactic haemostatic treatment within 3 days prior to this trial
Male
No healthy subjects accepted to join the trial.
Subject must be at least 16 Years old.


Patient description (medical language): A 20-year-old man comes to the emergency due to bleeding after a tooth extraction.  The bleeding has persisted for approximately 30 minutes despite constant direct pressure.  He is a known case of Hemophilia type A treated with FVIII. Blood pressure is 95/60 mm Hg and pulse is 105/min. His weight is 70 Kg. Family history is positive for Hemophilia type A in his maternal uncle. He also has a lipoma on his left arm which he plans to remove surgically. His FVIII activity is 40%.

Patient description (patient's own words): I got my tooth extracted and I could not stop bleeding for 30 min. I'm a 20 yo dude but I have Hemophilia type A treated with FVIII. My blood pressure was 95/60 and my pulse 105/min. I'm 70 kg. My uncle on my mom's side also has type A hemophilia. I also have a fatty swelling on my left arm and I was supposed to remove it. My FVIII activity was 40%.

Does the patient match the trial criteria? 0
Clinical trial: Neuropsychological Assessment of Children and Adolescents With Turner Syndrome (NCT03812913)

Eligibility criteria:
INCLUSION CRITERIA

        Turner syndrome group :

          -  girls with diagnosed Turner syndrome.

        Isolated GHD group :

          -  girls with diagnosed isolated growth hormone deficiency

        All participants :

          -  age between 7 years to 16 years and 11 months.

          -  informed consent signed by the participant and her parents (or her legal
             representatives)

          -  being registered in the national social security system

        EXCLUSION CRITERIA :

        Turner syndrome group :

          -  patients with chronic pathology other than Turner syndrome.

          -  karyotype : part of a Y chromosome and r(X) cases.

          -  medical treatment other than those usually prescribed in patients with Turner
             syndrome.

        Isolated GHD group :

          -  patients with chronic pathology other than isolated growth hormone deficiency.

          -  medical treatment other than those usually prescribed in patients with isolated growth
             hormone deficiency.

        All participants :

          -  diagnosed intellectual disability (IQ<70) or intellectual giftedness

          -  history of acquired brain injury

          -  sensory disturbances (auditory or visual) incompatible with the achievement of
             neuropsychological tasks.

          -  insufficient French language proficiency
Female
No healthy subjects accepted to join the trial.
Subject must be at least 7 Years old.
Subject must be at most 16 Years

Patient description (medical language): A 9-year-old girl is brought to the office for evaluation of short stature and overweight body habitus. The patient's mother and father are 170 cm and 181 cm tall, respectively.  On physical examination, the patient's height is in the 5th percentile of her age.  Other findings include low-set ears, a high arched palate, a webbed neck, and cubitus valgus.  Chromosomal analysis reveals a 45, XO karyotype.

Patient description (patient's own words): I took my 9-year-old daughter to the doctor because my mother-in-law kept saying she seemed small and overweight. My husband and I are 170 cm and 181 cm tall, respectively. The physical health highlighted that she is in the 5th percentile of her age. The doctor said that she has low-set ears, a high-arched palate, a webbed neck, and cubitus valgus. She also did a chromosomal analysis, which revealed a 45, XO karyotype.

Does the patient match the trial criteria? 1
Clinical trial: Ultra-low Dose Chest Computed Tomography: a Rule-out Tool for Community-acquired Pneumonia (NCT04541160)

Eligibility criteria:
Inclusion Criteria:

          -  Suspected CAP;

          -  At least one respiratory symptom (new or increasing cough, expectoration, dyspnea or
             chest pain) and

          -  At least one symptom related to infection (fever ≥ 38°C, chills, sweating, myalgia,
             mental confusion or headache) and

          -  Focal auscultatory findings during physical examinations (crackling rales)

          -  No definitive diagnosis possible by clinical judgment.

        Exclusion Criteria:

          -  Score in at least one clinical part of the CURB-65 or PSA scores

          -  Clinical diagnosis of rhinosinusitis and acute nasopharyngitis and who had already
             been treated with antimicrobial therapy for this episode of disease

          -  pregnancy;

          -  the presence of other respiratory diseases such as chronic obstructive pulmonary
             disease (COPD), asthma, interstitial lung disease, chronic diseases or other chronic
             airway conditions;

          -  diagnosis of congestive heart failure;

          -  body mass index (BMI) greater than 30;

          -  inability to hold the breath for at least 10 seconds
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Patient description (medical language): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient description (patient's own words): I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Does the patient match the trial criteria? 0
Clinical trial: Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease (NCT00998244)

Eligibility criteria:
Inclusion Criteria:

          -  18 to 70 years old

          -  BMI between 30 kg/m2 and 45 kg/m2

        Exclusion Criteria:

          -  Known history of Barrett's esophagus or esophageal adenocarcinoma

          -  Previous surgical anti-reflux procedure

          -  Previous weight loss surgery, including gastric bypass

          -  Diabetes

          -  Pregnancy

          -  Heart Disease

          -  Unwillingness to discontinue use of proton pump inhibitors (PPI's) or H2-receptor
             antagonists per study protocol
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 70 Years

Patient description (medical language): A 48-year-old man comes to the office complaining of heartburn and acid reflux.  He has taken over-the-counter antacids but sees no relief.  Other medical history is unremarkable.  The patient does not use tobacco, alcohol, or illicit drugs.  Vital signs are within normal limits.  BMI is 31 kg/m2.  Physical examination is  positive for mild tenderness in upper stomach. Chest x-ray shows an air-fluid opacity behind the heart.  A barium swallow study reveals approximately 1/3 of the stomach herniating through the esophageal hiatus.

Patient description (patient's own words): I went to my doctor's office because of a non-stop heartburn and some acid reflux. I took over-the-counter medications, but it keeps going strong! I don't smoke, take drugs or drink alcohol, I'm healthy! The doctor took my vitals, which turned out normal. My BMI is 31, which might be a bit too much for a 48-year-old guy like me. They examined my stomach and found a mild tenderness in the upper part. I also did some X-rays, and they found out that I have an air-fluid opacity behind my heart. I did another X-ray, and it turns out that a part of my stomach went up my chest through a hole in my diaphragm!

Does the patient match the trial criteria? 1
Clinical trial: Molecular Analysis of Patients With Neuromuscular Disease (NCT00390104)

Eligibility criteria:
The samples used in this study will be derived from individuals at risk for, or suffering
        from, neuromuscular disease, generally resulting in clinical weakness of one or more muscle
        groups and their family members.

        Inclusion criteria:

          1. having a clinical and/or pathological diagnosis of a muscular dystrophy

          2. being the first degree relative of someone with such a diagnosis

          3. having had a muscle biopsy if diagnosed with a neuromuscular disease

          4. willingness to provide a skin biopsy for research only

        Exclusion Criteria:

          1. not having such a diagnosis and not being related to such an individual

          2. not wishing to participate

          3. being incapable of giving consent and not having a legal guardian willing or able to
             do so
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.

Subject must be at most 100 Years

Patient description (medical language): A 47-year-old man comes to the clinic for the follow up of his neuromuscular disease. He experienced gradual, progressive weakness of the left upper extremity over the last year.  Over the last few months, he has also noticed weakness in the right upper extremity.  BP is 120/75, PR is 80 and temperature is 37 C. Reflexes are brisk in the upper extremities, and the plantar responses are extensor.  Mild gait ataxia is present. The patient is under treatment of Riluzole 50 mg BID with the diagnosis of ALS.

Patient description (patient's own words): I've been suffering from a neuromuscular disease for a while now, and I went to my doctor's office. I'm now a 47-year-old man and over the past year I experienced a progressive and gradual weakness of my left upper extremity, and over the past month, I also noticed a weakness over my right upper extremity. My heart rate was 120/75, and my  PR was 80 with 37°C for temperature. My reflexes are not good in my upper extremities, and I have trouble with my balance. I'm also under Exservan 50 mg for my sclerosis.

Does the patient match the trial criteria? 0
Clinical trial: Laparoscopic TEP (Total Extra-peritoneal) Repair Vs Open PHS (Prolene Hernia System) (NCT03842852)

Eligibility criteria:
Inclusion Criteria:

          -  For laparoscopic repair: bilateral inguinal hernia or recurrent hernia For open
             repair: Patients with unilateral inguinal hernia More than 18 years old. Both sexes

        Exclusion Criteria:

          -  Patient under 18 years old Patients who cannot sign the informed consent.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.



Patient description (medical language): A 49-year-old man comes to the office because of the bulging in his groin.  Physical examination shows a swelling above the inguinal ligament. When the patient is asked to cough, the size of the bulge increases.  His medical history is significant for mild dyslipidemia, which is under control by lifestyle modifications. He does not smoke, but drinks alcohol occasionally. His vital signs and other physical examinations are unremarkable. He is referred to a surgeon and scheduled to undergo elective laparoscopic hernia repair.

Patient description (patient's own words): I'm a 49-year-old man and I went to my doctor the other day because I could not stand that sharp pain in my upper thigh, it was so swollen! The doctor told me that it was swollen right next to my ligament. It's even bigger when I'm coughing. I'm suffering from high cholesterol and I already had to adapt my lifestyle to keep the disease under control. I do not smoke but to be honest I still drink from time to time. The doctor found my vitals normal. She gave me a note to see a surgeon to get my mass removed and get a hernia repair.

Does the patient match the trial criteria? 1